SeP, a hepatokine shown to display a protective antioxidant role in all stages of NAFLD, with a therapeutic benefit (132), has nevertheless been incriminated in liver fibrosis and IR (129). The gene discussed is SELENOP; the disease is metabolic dysfunction-associated steatotic liver disease.